Clarisonic Skin Cleanser Cracks $40M in Sales on Kudos From Oprah and YouTube Beauty Queen

$225 model that can clean the face and other parts of the body, and a lower-end $149 model that is “cute and tiny,” Giuliani says. The company maintains active R&D at its Bellevue offices, but Giuliani wouldn’t say anything in detail about any new products Clarisonic has in the pipeline.

The company has two distinct markets it is pursuing now. One is with professional dermatologists, who use the device to clean patients’ skin before they undergo ultraviolet treatments for acne, or spas like Gene Juarez that use it to prep customers for facials, or microdermabrasions. The other market segment is through high-end retailers like Saks Fifth Avenue, Sephora, and Nordstrom.

So far, no direct competitors have entered this market yet, and no big players have shown they are making a serious R&D effort, Giuliani says. It could be that these huge skin-care players, like Olay from Procter & Gamble, consider $40 million in annual revenue to be such small potatoes that it’s not worth their time, Giuliani says.

“The real competition is with how people are used to spending their money on facial care,” Giuliani says. “This is still a new way of treating the skin.”

Giuliani isn’t shying away from comparing his new company to the success with Sonicare. He noted that Clarisonic’s offices today are in the very same building from Sonicare’s early days, a 1970s-style, low-rise office and industrial area a few blocks from I-90.

He clearly has high ambitions for Clarisonic, and they appear to have grown over time. Back in 2004, he told The Seattle Times he planned to be less involved with the operations of Clarisonic than he was with Sonicare, and that he’d quit once the skin-care product was on the market for six months.

Five years later, he’s still the CEO. Now 63, Giuliani says he likes to skip from project to project at the company, getting personally involved in R&D, marketing, and manufacturing—whatever is needed at a given phase. When I asked if he plans to sell the company, he made it sound like he’s in no hurry to hand over the reins.

“We’re still at the beginning,” Giuliani says. “We’ve only reached a fraction of the potential.”

Author: Luke Timmerman

Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.